Swiss National Bank Sells 11,300 Shares of Axonics, Inc. (NASDAQ:AXNX)

Swiss National Bank lowered its position in shares of Axonics, Inc. (NASDAQ:AXNX - Free Report) by 10.2% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 99,400 shares of the company's stock after selling 11,300 shares during the period. Swiss National Bank owned 0.20% of Axonics worth $6,186,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Headlands Technologies LLC acquired a new stake in shares of Axonics in the 4th quarter worth approximately $53,000. RiverPark Advisors LLC acquired a new stake in Axonics during the 3rd quarter worth about $58,000. C M Bidwell & Associates Ltd. lifted its stake in Axonics by 108.2% during the third quarter. C M Bidwell & Associates Ltd. now owns 1,270 shares of the company's stock valued at $71,000 after buying an additional 660 shares in the last quarter. Sentry Investment Management LLC acquired a new position in shares of Axonics in the fourth quarter worth about $125,000. Finally, Covestor Ltd increased its position in shares of Axonics by 40.8% in the third quarter. Covestor Ltd now owns 3,143 shares of the company's stock worth $176,000 after acquiring an additional 911 shares in the last quarter. 99.48% of the stock is owned by institutional investors.

Axonics Stock Performance

Shares of NASDAQ AXNX traded down $0.12 during mid-day trading on Friday, reaching $67.55. The company had a trading volume of 236,660 shares, compared to its average volume of 1,116,316. The stock has a market capitalization of $3.45 billion, a PE ratio of -211.09 and a beta of 0.60. Axonics, Inc. has a twelve month low of $47.59 and a twelve month high of $69.68. The stock's 50 day moving average is $67.72 and its 200-day moving average is $64.28.

Axonics (NASDAQ:AXNX - Get Free Report) last issued its earnings results on Tuesday, April 30th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.32). The firm had revenue of $91.41 million during the quarter, compared to analyst estimates of $89.79 million. Axonics had a negative return on equity of 2.58% and a negative net margin of 4.12%. The business's revenue for the quarter was up 29.4% on a year-over-year basis. During the same period in the previous year, the company earned ($0.19) earnings per share. On average, sell-side analysts anticipate that Axonics, Inc. will post 0.13 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages recently commented on AXNX. Needham & Company LLC restated a "hold" rating on shares of Axonics in a research report on Monday, May 6th. Royal Bank of Canada reissued a "sector perform" rating and set a $71.00 target price on shares of Axonics in a research note on Thursday, February 29th. Eight research analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat, Axonics presently has a consensus rating of "Hold" and an average target price of $70.73.

Axonics Profile

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.